Abstract
Background: Integrin α6β4 is a known tumor antigen; however, its function in different subtypes of thyroid cancer is not known. This study reports that α6β4 expression is selectively up-regulated in anaplastic thyroid cancer (ATC) cells, the most malignant subtype of human thyroid cancer. Materials and Methods: To assess the contribution of α6β4 in ATC progression, cell proliferation, motility and soft agar assay were performed in vitro and a xenograft tumor growth assay was performed in vivo. Results: Knockdown of β4 integrin subunit expression by shRNA in ATC cells reduced the proliferation, migration, and anchorage-independent growth of ATC cells in vitro and xenograft tumor growth in vivo. Conclusion: These data suggest that integrin α6β4 contributes to the development of aggressive forms of thyroid cancer with poor prognostic potential, such as ATC, and thus may be a novel therapeutic target for the treatment for this subtype of thyroid cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 4485-4492 |
| Number of pages | 8 |
| Journal | Anticancer research |
| Volume | 30 |
| Issue number | 11 |
| Publication status | Published - 2010 Nov 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Effect of β4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma. / Noh, Tae Woong; Soung, Young Hwa; Kim, Hong Im; Gil, Hyea Jin; Kim, Jeong Mo; Lee, Eun Jig; Chung, Jun.
In: Anticancer research, Vol. 30, No. 11, 01.11.2010, p. 4485-4492.Research output: Contribution to journal › Article
TY - JOUR
T1 - Effect of β4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma
AU - Noh, Tae Woong
AU - Soung, Young Hwa
AU - Kim, Hong Im
AU - Gil, Hyea Jin
AU - Kim, Jeong Mo
AU - Lee, Eun Jig
AU - Chung, Jun
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Background: Integrin α6β4 is a known tumor antigen; however, its function in different subtypes of thyroid cancer is not known. This study reports that α6β4 expression is selectively up-regulated in anaplastic thyroid cancer (ATC) cells, the most malignant subtype of human thyroid cancer. Materials and Methods: To assess the contribution of α6β4 in ATC progression, cell proliferation, motility and soft agar assay were performed in vitro and a xenograft tumor growth assay was performed in vivo. Results: Knockdown of β4 integrin subunit expression by shRNA in ATC cells reduced the proliferation, migration, and anchorage-independent growth of ATC cells in vitro and xenograft tumor growth in vivo. Conclusion: These data suggest that integrin α6β4 contributes to the development of aggressive forms of thyroid cancer with poor prognostic potential, such as ATC, and thus may be a novel therapeutic target for the treatment for this subtype of thyroid cancer.
AB - Background: Integrin α6β4 is a known tumor antigen; however, its function in different subtypes of thyroid cancer is not known. This study reports that α6β4 expression is selectively up-regulated in anaplastic thyroid cancer (ATC) cells, the most malignant subtype of human thyroid cancer. Materials and Methods: To assess the contribution of α6β4 in ATC progression, cell proliferation, motility and soft agar assay were performed in vitro and a xenograft tumor growth assay was performed in vivo. Results: Knockdown of β4 integrin subunit expression by shRNA in ATC cells reduced the proliferation, migration, and anchorage-independent growth of ATC cells in vitro and xenograft tumor growth in vivo. Conclusion: These data suggest that integrin α6β4 contributes to the development of aggressive forms of thyroid cancer with poor prognostic potential, such as ATC, and thus may be a novel therapeutic target for the treatment for this subtype of thyroid cancer.
UR - http://www.scopus.com/inward/record.url?scp=78650253820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650253820&partnerID=8YFLogxK
M3 - Article
C2 - 21115897
AN - SCOPUS:78650253820
VL - 30
SP - 4485
EP - 4492
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 11
ER -